Advocacy intelligence hub — real-time data for patient organizations
Solid Biosciences Inc. — PHASE1
Agiana Pharmaceuticals — PHASE2
Royal Brompton & Harefield NHS Foundation Trust
So-Aqueous: FDA approved
For use as a substitute for oral sotalol in patients who are unable to take sotalol orally [oral sotalol is indicated for maintenance of normal sinus rhythm in patients with history of highly symptomatic atrial fibrillation /flutter, and for treatment of documented life-threatening ventricular arrhythmias]
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
So-Aqueous
AltaThera Pharmaceuticals LLC
So-Aqueous
(sotalol (IV))Orphan drugAltaThera Pharmaceuticals LLC
Cordarone
(Amiodarone HCl)Orphan drugstandardWyeth-Ayerst Laboratories
Browse all Catecholaminergic polymorphic ventricular tachycardia news →
Laurent Servais
Centre Hospitalier Universitaire de Liege
Prince J Kannankeril, MD, MSCI, MD
Vanderbilt University Medical Center
📍 NASHVILLE, TN
Lia Crotti
University of Milano-Bicocca
Jacob Tfelt-Hansen
The Heart Centre
Catherine E Renwick
Royal Brompton & Harefield NHS Foundation Trust
Jason Homsy, MD, PhD
Executive Medical Director
📍 BOSTON, MA
View all Catecholaminergic polymorphic ventricular tachycardia specialists →